Literature DB >> 9445137

Leiomyosarcoma in soft tissue: examination of p53 status and cell proliferating factors in different locations.

T Konomoto1, T Fukuda, K Hayashi, J Kumazawa, M Tsuneyoshi.   

Abstract

The biological behavior of soft tissue leiomyosarcoma varies with its location: tumors in deep soft tissue show a worse prognosis than those in superficial soft tissue. In this study, we analyzed cell proliferating factors (mitotic and Ki-67 indices) and the p53 status of both types of leiomyosarcoma (37 cases) to evaluate the possibility that these factors may serve as indicators in prognosis. Expression of both of the cell proliferating factors were higher in the superficial type, but these differences were not significant. The incidence of abnormal p53 detected by immunohistochemistry and mutation analysis was also higher in the superficial type, but, again, no significant difference was observed. Abnormal p53 and a high Ki-67 index in the deep type, and a large tumor size (>6 cm) in the superficial type may be useful as prognostic factors. Interestingly, all of the superficial cases who died of the disease showed abnormal p53. In conclusion, these two types of leiomyosarcoma are essentially the same, and their location remains a good prognostic factor. Furthermore, abnormality of the p53 gene was related to a poor prognosis regardless of the tumor's anatomic location.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445137     DOI: 10.1016/s0046-8177(98)90393-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.

Authors:  T Noguchi; Y Dobashi; H Minehara; M Itoman; T Kameya
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.

Authors:  Ching-Yao Yang; Jau-Yu Liau; Wei-Ju Huang; Yu-Ting Chang; Ming-Chu Chang; Jen-Chieh Lee; Jia-Huei Tsai; Yi-Ning Su; Chia-Cheng Hung; Yung-Ming Jeng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection.

Authors:  Jeremiah L Deneve; Jane L Messina; Marilyn M Bui; Suroosh S Marzban; G Douglas Letson; David Cheong; Ricardo J Gonzalez; Vernon K Sondak; Jonathan S Zager
Journal:  Cancer Control       Date:  2013-10       Impact factor: 3.302

Review 4.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

5.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Authors:  Elisabetta Pennacchioli; Giulio Tosti; Massimo Barberis; Tommaso M De Pas; Francesco Verrecchia; Claudia Menicanti; Alessandro Testori; Giovanni Mazzarol
Journal:  Clin Exp Metastasis       Date:  2012-06-15       Impact factor: 5.150

6.  The relation between histological, tumor-biological and clinical parameters in deep and superficial leiomyosarcoma and leiomyoma.

Authors:  Justin Pijpe; Gerben H Torn Broers; Boudewijn E Ch Plaat; M Hundeiker; F Otto; Mirjam F Mastik; Harald J Hoekstra; Winette T A van der Graaf; Eva van Den Berg; Willemina M Molenaar
Journal:  Sarcoma       Date:  2002
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.